Considering the low utilization of NAT nationally and its potential benefits, these findings should serve as the foundation for future prospective and randomized trials designed to generate necessary data to establish guidelines for the sequencing of treatment for resectable ICC. This evidence concerns the gene BRD2 and intrahepatic cholangiocarcinoma.